Close this search box.
Follow us

Understanding Type 2 Diabetes and Medications for Management

Type 2 diabetes

  Type 2 diabetes is a prevalent chronic condition, that affects millions of people worldwide. It occurs when the body cannot effectively use the insulin it produces, leading to elevated blood sugar levels. Proper management of Type 2 diabetes is crucial to prevent complications and improve the quality of life for those diagnosed. In addition […]

Dapagliflozin in Patients with Type 2 Diabetes


Benefits of Dapagliflozin When in Patients with Type 2 Diabetes Abstracts Dapagliflozin reduces the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes whether or not they were also taking various cardiovascular (CV) medications. The study that has published in JAMA Cardiology, explored whether the diuretic and antihypertensive effects of dapagliflozin, a sodium-glucose cotransporter […]

increase Risk of Developing Diabetes

Risk of Developing Diabetes

  COVID-19 infection even mild ones may increase Risk of Developing Diabetes A recent study followed people with mild COVID-19 to analyze whether or not they had an increased risk of developing diabetes. As a sway, they also tracked individuals with an acute upper respiratory tract infection (AURI). The researchers concluded that individuals with mild […]

Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Overview of Type 2 Diabetes Mellitus Type 2 diabetes mellitus is the most common type of diabetes, in which the blood glucose, is too high. This chronic condition may lead to disorders of the circulatory, nervous and immune systems, and affects your everyday life. In type 2 diabetes there are mainly 2 associated problems; body […]

US FDA Approved Empagliflozin


The U.S. FDA Approved Empagliflozin for Wider Range of Patients with Heart Failure   Abstracts: On February 24, 2022, The U.S. FDA approved an expanded indication for empagliflozin which is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to reduce the risk of Cardiovascular (CV) death and Heart failure (HF) hospitalization in adults with HF with reduced or […]